XOMA Corp (NASDAQ:XOMA) – Wedbush issued their Q1 2021 EPS estimates for shares of XOMA in a report released on Monday, March 23rd. Wedbush analyst L. Moussatos forecasts that the biotechnology company will post earnings per share of ($0.10) for the quarter. Wedbush has a “Buy” rating and a $29.00 price objective on the stock. Wedbush also issued estimates for XOMA’s Q2 2021 earnings at ($0.12) EPS, Q3 2021 earnings at ($0.11) EPS and Q4 2021 earnings at ($0.12) EPS.

Other equities research analysts have also issued research reports about the company. ValuEngine raised XOMA from a “sell” rating to a “hold” rating in a research note on Saturday, February 15th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of XOMA in a research report on Monday, March 9th. Finally, Zacks Investment Research reissued a “hold” rating on shares of XOMA in a report on Saturday, March 14th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. XOMA presently has a consensus rating of “Buy” and an average target price of $28.67.

XOMA opened at $17.25 on Thursday. The business’s fifty day simple moving average is $22.72 and its 200 day simple moving average is $22.54. XOMA has a 52 week low of $11.58 and a 52 week high of $28.85. The company has a quick ratio of 6.76, a current ratio of 6.76 and a debt-to-equity ratio of 0.63. The stock has a market cap of $169.76 million, a PE ratio of -31.36 and a beta of 1.12.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). XOMA had a negative return on equity of 11.53% and a negative net margin of 18.01%. The company had revenue of $0.42 million for the quarter, compared to the consensus estimate of $3.24 million.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XOMA. BVF Inc. IL grew its position in XOMA by 47.1% during the 4th quarter. BVF Inc. IL now owns 2,642,405 shares of the biotechnology company’s stock worth $72,138,000 after acquiring an additional 845,463 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of XOMA during the fourth quarter valued at approximately $2,450,000. Credit Suisse AG bought a new position in shares of XOMA in the fourth quarter worth approximately $1,472,000. Marshall Wace LLP bought a new position in shares of XOMA in the fourth quarter worth approximately $1,229,000. Finally, EAM Investors LLC purchased a new position in shares of XOMA in the fourth quarter worth $1,052,000. 46.67% of the stock is owned by institutional investors.

In other XOMA news, major shareholder Value Fund L. P. Biotechnology purchased 118,277 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was acquired at an average cost of $16.90 per share, for a total transaction of $1,998,881.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bvf Partners L. P/Il purchased 100,000 shares of the business’s stock in a transaction on Friday, March 13th. The shares were acquired at an average price of $18.34 per share, with a total value of $1,834,000.00. The disclosure for this purchase can be found here. Insiders have acquired 220,277 shares of company stock worth $3,866,681 over the last three months. Insiders own 9.89% of the company’s stock.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

See Also: What are the advantages to having securities held in street name?

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.